アブストラクト
| Title | 腎疾患合併の糖尿病患者へのSGLT2阻害薬 |
|---|---|
| Subtitle | 特集1 アウトカムを意識した SGLT2阻害薬・インクレチン関連薬の使い方 SGLT2阻害薬の多面的作用 |
| Authors | 久米真司 |
| Authors (kana) | |
| Organization | 滋賀医科大学糖尿病内分泌・腎臓内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 1 |
| Page | 39-42 |
| Year/Month | 2023 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Point」●SGLT2阻害薬は近位尿細管細胞でのグルコース再吸収を抑制し血糖値を下げる糖尿病治療薬である. ●SGLT2阻害薬は血糖降下作用を超えた腎保護効果をもつ糖尿病治療薬である. ●SGLT2阻害薬はアルブミン尿減少効果をもつ糖尿病治療薬である. ●SGLT2阻害薬はアルブミン尿期によらず腎機能低下を抑制する可能性がある糖尿病治療薬である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Wanner C, et al;EMPA-REG OUTCOME Investigators:Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med, 375:323-334, 2016
- 2) Neal B, et al;CANVAS Program Collaborative Group: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med, 377:644-657, 2017
- 3) Wiviott SD, et al;DECLARE-TIMI 58 Investigators: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 380:347-357, 2019
- 4) Cherney DZI, et al;VERTIS CV Investigators:Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 64:1256-1267, 2021
- 5) Perkovic V, et al;CREDENCE Trial Investigators: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 380:2295-2306, 2019
残りの9件を表示する
- 6) Heerspink HJL, et al;DAPA-CKD Trial Committees and Investigators:Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 383:1436-1446, 2020
- 7) Kidokoro K, et al:Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Circulation, 140:303-315, 2019
- 8) Tanaka S, et al:Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int, 94:912-925, 2018
- 9) Kamezaki M, et al:Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci Rep, 8:4029, 2018
- 10) Takagi S, et al:Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig, 9:1025-1032, 2018
- 11) Sano M, et al:Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J Clin Med Res, 8:844-847, 2016
- 12) Tomita I, et al:SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metab, 32:404-419.e6, 2020
- 13) Neuen BL, et al:Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. J Am Soc Nephrol, 30:2229-2242, 2019
- 14) Jongs N, et al;DAPA-CKD Trial Committees and Investigators:Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes:a prespecified analysis from the DAPACKD trial. Lancet Diabetes Endocrinol, 9:755-766, 2021
